Latest market price
11.76
-0.23-1.92%
ANGOQT48AngioDynamics, Inc.·NASDAQ
11.76-1.92%
TA
Loading chart...
Signal & projected range
Insider open-market saleHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
Snapshot
Index—P/E—EPS (ttm)-0.79Insider Own6.90%Shs Outstand42.05MPerf Week-3.37%
Market Cap494.56MForward P/E—EPS next Y-0.10Insider Trans-1.68%Shs Float37.21MPerf Month-22.17%
Enterprise Value471.56MPEG—EPS next Q-0.10Short Float5.15%Perf Quarter-22.58%
Income-32.00MP/S1.52EPS this Y—Short Ratio3.19Perf Half Y7.10%
Sales325.00MP/B3.02EPS next Y—ROA-13.61%Short Interest1.92MPerf YTD-8.41%
Book/sh3.90P/C14.55EPS next 5Y—ROE-19.25%52W High16.29 -27.81%Perf Year-3.13%
Cash/sh0.81P/FCF—EPS past 3/5Y—ROIC-19.87%52W Low9.39 25.24%Perf 3Y89.68%
Dividend Est.—EV/EBITDA—Sales past 3/5Y-1.90% 1.92%Gross Margin55.65%Volatility3.67% 5.63%Perf 5Y-58.75%
Dividend TTM—EV/Sales1.45EPS Y/Y TTM—Oper. Margin-11.24%ATR (14)0.59Perf 10Y-30.37%
Dividend Ex-Date—Quick Ratio1.48Sales Y/Y TTM7.97%Profit Margin-10.12%RSI (14)37.23Recom2.55
Dividend Gr. 3/5Y—Current Ratio2.40EPS Q/Q60.00%SMA20-1.87%Beta0.26Target Price19.00
Payout0.00%Debt/Eq0.07Sales Q/Q6.58%SMA50-16.61%Rel Volume0.71Prev Close11.99
Employees632LT Debt/Eq0.05EarningsJan 06SMA200-5.77%Avg Volume638.61KPrice11.76
IPO DateJun 01, 2004Option/ShortYes / YesEPS/Sales Surpr.64.44% 0.50%Net Debt/EBITDA—Volume456,631Change-1.92%
Analyst Ratings
DateActionAnalystRatingTarget
Oct-13-26ReiteratedHC Wainwright & Co.Buy$19 → $18
Jul-15-26ReiteratedCanaccord GenuityBuy$18 → $20
Jul-15-26ReiteratedHC Wainwright & Co.Buy$14 → $19
Oct-03-25ReiteratedCanaccord GenuityBuy$17 → $18
Jul-16-25ReiteratedCanaccord GenuityBuy$12 → $17
Oct-04-24ReiteratedCanaccord GenuityBuy$12
Sep-20-24ReiteratedHC Wainwright & Co.Buy$14
Apr-05-24UpgradeOppenheimerPerform → Outperform$12
Apr-17-23DowngradeRaymond JamesStrong Buy → Outperform
Jan-06-23ReiteratedRaymond JamesStrong Buy$27 → $22
Latest News· Times ET
Oct-29-26
Oct-21-26
Oct-15-26
Oct-14-26
Oct-13-26
Oct-09-26
Oct-08-26
Company

AngioDynamics, Inc. specializes in the development, manufacturing, and commercialization of a diverse array of medical, surgical, and diagnostic instruments. These products are utilized by healthcare professionals to address conditions such as peripheral vascular disease, facilitate vascular access, and support various oncology and surgical interventions, serving both domestic and international markets. The company's portfolio includes advanced ablation systems like NanoKnife, designed for the precise surgical removal of soft tissues, and Solero microwave and radiofrequency systems, effective in ablating solid cancerous or benign growths. Additionally, they provide BioSentry tract sealant systems, IsoLoc Endorectal Balloons, Alatus vaginal balloon packing systems, angiographic catheters, guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits. Their endovascular therapies segment encompasses solutions for thrombus management, atherectomy procedures, core peripheral products, and the treatment of venous insufficiency. Furthermore, AngioDynamics is a key supplier of vascular access devices, such as peripherally inserted central catheters (PICCs), midline catheters, implantable ports, and dialysis catheters, along with associated accessories. These are primarily employed for short-duration systemic drug delivery, including chemotherapy and antibiotics, marketed under a robust portfolio of brand names such as BioFlo, BioFlo Midline, BioFlo PICC, Xcela PICC, PASV, BioFlo Port, SmartPort, Vortex, LifeGuard, BioFlo DuraMax, and DuraMax. The company distributes its offerings directly to a specialized clientele, including interventional radiologists, cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses, while also leveraging established distributor networks. Founded in 1988, AngioDynamics maintains its corporate headquarters in Latham, New York.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2026
5/31/2026
FY 2025
5/31/2025
FY 2024
5/31/2024
FY 2023
5/31/2023
FY 2022
5/31/2022
FY 2021
5/31/2021
FY 2020
5/31/2020
FY 2019
5/31/2019
Total Revenue325320292304—————
Cost of Goods Sold Incl. D&A144145135149—————
Gross Profit180175158155—————
Selling, General and Administrative Excl. Other158157145144—————
Research and Development31292632—————
Other Operating Expense292927171—————
Operating Income-35-40-40-192—————
Interest Expense
0000—————
Unusual Expense
—————————
Non-Operating Income (Expense)3461—————
Net Income Before Taxes-32-36-34-192—————
Income Taxes000-7—————
Consolidated Net Income-32-37-34-184—————
Net Income From Continuing Operations-32-37-34-184—————
Net Income-32-37-34-184—————
EPS (Recurring)-0.79-0.88-0.83-4.59—————
EPS (Basic, Before Extraordinaries)-0.79-0.88-0.83-4.59—————
EPS (Diluted)-0.79-0.88-0.83-4.59—————
EBITDA-902-6—————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio
—————————
Price To Sales Ratio1.521.511.430.83—————
Gross Margin55.3854.6954.1150.99—————
Operating Margin-10.77-12.50-13.70-63.16—————
Net Margin-9.85-11.56-11.64-60.53—————
Shares Outstanding42424140—————
Market Capitalization494482418252—————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$17.10$15.00$12.91$10.81$8.71● Close Price0.00K86.00K172.00K258.00K344.01KUSD Trades VolumeNovDec2026FebMarAprMayJunJulAugSepOctNov
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Trowbridge Stephen AEVP and CFOOct 29 '26Sale12.2723,615289,756280,461Oct 30
Trowbridge Stephen AEVP and CFOOct 28 '26Sale12.171,72020,932304,076Oct 30
Nighan Warren JRSVP Quality and RegulatoryJul 30 '26Sale14.7223,370344,00664,745Jul 31
Piccinini LauraSVP InternationalJul 22 '26Option Exercise0.0036,383086,435Jul 24
Nighan Warren JRSVP Quality and RegulatoryJul 22 '26Option Exercise0.0025,746089,786Jul 24
Trowbridge Stephen AEVP and CFOJul 22 '26Option Exercise0.0073,6770314,115Jul 24
Clemmer James CPresident and CEOJul 22 '26Option Exercise0.00236,7190889,176Jul 24
Campbell Chad ThomasSVP/GM, Vascular AccessJul 22 '26Option Exercise0.0029,2340111,006Jul 24
Weiss Lawrence TSVP, Chief Legal OfficerOct 21 '25Buy11.8110,000118,10093,597Oct 22
Trowbridge Stephen AEVP and CFOOct 13 '25Buy11.168909,932256,629Oct 14
Clemmer James CPresident and CEOOct 09 '25Buy11.1510,000111,500882,529Oct 09
Nighan Warren JRSVP Quality and RegulatoryJan 16 '25Sale12.314,06049,97941,817Jan 17
Nighan Warren JRSVP Quality and RegulatoryOct 10 '24Buy6.0810060845,877Oct 10
Nighan Warren JRSVP Quality and RegulatoryOct 07 '24Buy6.097684,67745,777Oct 10
Trowbridge Stephen AEVP and CFOOct 08 '24Buy5.861,7009,962172,711Oct 08
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.